Bausch Health Companies (TSE:BHC) Stock Price Down 3.8% – Should You Sell?

Bausch Health Companies Inc. (TSE:BHC)’s stock price was down 3.8% on Friday . The stock traded as low as C$8.09 and last traded at C$8.10. Approximately 665,687 shares were traded during mid-day trading, an increase of 22% from the average daily volume of 545,133 shares. The stock had previously closed at C$8.42.

Analyst Ratings Changes

Separately, Jefferies Financial Group upgraded shares of Bausch Health Companies to a “hold” rating in a report on Wednesday, July 22nd. Three equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has an average rating of “Hold”.

Bausch Health Companies Trading Down 3.8%

The company has a quick ratio of 0.58, a current ratio of 1.44 and a debt-to-equity ratio of -1,173.29. The business’s fifty day simple moving average is C$8.13 and its two-hundred day simple moving average is C$7.65. The company has a market cap of C$3.03 billion, a price-to-earnings ratio of -2.76, a PEG ratio of 0.21 and a beta of 0.71.

Bausch Health Companies (TSE:BHC) last issued its earnings results on Wednesday, July 29th. The company reported C$1.79 earnings per share (EPS) for the quarter. The business had revenue of C$4.05 billion during the quarter. Bausch Health Companies had a negative net margin of 12.02% and a positive return on equity of 87.57%. On average, equities analysts predict that Bausch Health Companies Inc. will post 5.5472637 EPS for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.